Literature DB >> 24267294

Epidemiology of pulmonary arterial hypertension.

Darren B Taichman1, Jess Mandel.   

Abstract

Changes in the epidemiology of pulmonary arterial hypertension (PAH) have resulted from changes in classification schemes and an increased emphasis on diagnosis because of the availability of effective therapies. The terms primary pulmonary hypertension and secondary pulmonary hypertension are considered inappropriate, confusing, and should not be used. Recent registries of patients with PAH have provided improved data regarding prognosis in the era of advanced therapies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anorectic drugs; HIV infection; Hemolytic anemia; Idiopathic pulmonary arterial hypertension; Portopulmonary hypertension; Pulmonary arterial hypertension; Pulmonary veno-occlusive disease; Systemic sclerosis

Mesh：

Year:  2013        PMID： 24267294     DOI： 10.1016/j.ccm.2013.08.010

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN： 0272-5231            Impact factor:   2.878


  16 in total

Review 1.  ORAI channels in cellular remodeling of cardiorespiratory disease.

Authors:  Martin Johnson; Mohamed Trebak
Journal:  Cell Calcium       Date:  2019-02-08       Impact factor: 6.817

2.  Ethosome-Derived Invasomes as a Potential Transdermal Delivery System for Vardenafil Hydrochloride: Development, Optimization and Application of Physiologically Based Pharmacokinetic Modeling in Adults and Geriatrics.

Authors:  Hussein O Ammar; Mina Ibrahim Tadros; Nahla M Salama; Amira Mohsen Ghoneim
Journal:  Int J Nanomedicine       Date:  2020-08-06

Review 3.  Implications of Hydrogen Sulfide in Development of Pulmonary Hypertension.

Authors:  Yan Sun; Chaoshu Tang; Hongfang Jin; Junbao Du
Journal:  Biomolecules       Date:  2022-06-01

4.  Role of miR-21-5p/FilGAP axis in estradiol alleviating the progression of monocrotaline-induced pulmonary hypertension.

Authors:  Xiaoyi Hu; Qian Wang; Hui Zhao; Wenhui Wu; Qinhua Zhao; Rong Jiang; Jinming Liu; Lan Wang; Ping Yuan
Journal:  Animal Model Exp Med       Date:  2022-06-17

5.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

6.  Animal Models of Pulmonary Hypertension: Matching Disease Mechanisms to Etiology of the Human Disease.

Authors:  Kelley L Colvin; Michael E Yeager
Journal:  J Pulm Respir Med       Date:  2014-08-04

7.  Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study.

Authors:  Robert P Frantz; Robert J Schilz; Murali M Chakinala; David B Badesch; Adaani E Frost; Vallerie V McLaughlin; Robyn J Barst; Daniel M Rosenberg; Dave P Miller; Brian K Hartline; Wade W Benton; Harrison W Farber
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

8.  Complex inheritance in Pulmonary Arterial Hypertension patients with several mutations.

Authors:  Guillermo Pousada; Adolfo Baloira; Diana Valverde
Journal:  Sci Rep       Date:  2016-09-15       Impact factor: 4.379

9.  Functional assessment of the BMPR2 gene in lymphoblastoid cell lines from Graves' disease patients.

Authors:  Guillermo Pousada; Mauro Lago-Docampo; Sonia Prado; Rubén Varela-Calviño; Beatriz Mantiñán; Diana Valverde
Journal:  J Cell Mol Med       Date:  2017-12-20       Impact factor: 5.310

Review 10.  MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction.

Authors:  Ji-Ru Zhang; Hai-Jian Sun
Journal:  Hypertens Res       Date:  2020-09-23       Impact factor: 3.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.